The aim of this study was to determine whether two polymorphisms of the human interferon lambda 4 (IFNL4) gene (rs12979860 and rs8099917) can predict sustained virologic response (SVR) following antiviral therapy in patients with inherited bleeding disorder and chronic hepatitis C (CHC).
bleeding disorders, were particularly vulnerable to HCV exposure from non-screened blood and plasma-derived clotting factor concentrates. Most of these patients ultimately developed CHC. Treated or recombinant clotting factors are now utilized routinely, and new cases of HCV infection in patients with congenital bleeding disorders are uncommon. 2 The prevalence of hepatitis C among hemophilic patients varies from 24% to 95% throughout the world. 3 Prior to the introduction of efficacious HCV direct-acting antiviral agents (DAAs) in 2011, A 24-48 week course of Pegylated-Interferon-α-2a (PegIFN-α-2a) or PegIFN-α-2b combined with Ribavirin (RBV; PegIFN/RBV) was the recommended treatment for CHC. 4 In countries in which DAAs are not available, PegIFN/RBV remains an effective treatment option. HCV medications can lead to a sustained virologic response (SVR), which in turn improves patients' survivability and prevents disease progression and development of hepatocellular carcinoma (HCC).
Thus, treating CHC patients with available antiviral agents is highly recommended. 5, 6 However, certain factors, including host and viral parameters, can affect the treatment response to antiviral therapy and must be considered prior to starting any antiviral regimens. 7 Key viral determinants of response are HCV genotype-1 and HCV RNA level (high baseline viremia), both of which have negative effects ontreatment response. 8 In 2009, three genome-wide association studies (GWAS) found that single nucleotide polymorphisms (SNPs) in the interferon-λ (IFNL) genomic region, located on human chromosome 19, are associated with spontaneous and treatment-induced HCV clearance. [9] [10] [11] The most studied SNPs in this genomic region with regard to treatment response are rs12979860 and rs8099917, which were shown to be the strongest baseline predictors of SVR in patients with HCV genotype-1 infection. [12] [13] [14] In addition, the rs12979860 SNP was shown to be significantly associated with spontaneous clearance of HCV infection. 15, 16 Historically, the rs12979860 and rs8099917 SNPs have been referred to as IFNL3 (IL28B) polymorphisms, however, the discovery of the IFNL4 gene by Prokunina-Olsson et al. 17 localized the rs12979860 SNP on IFNL4.
Patients with congenital bleeding disorder and HCV comprise a special treatment group, with little data to support treatment recommendations. We conducted this study to evaluate the impact of host and viral factors on-treatment response to PegIFN/RBV in patients with congenital bleeding disorder and CHC to provide treatment guidance.
| MATERIALS AND METHODS

| Study population
In this retrospective study (2010) (2011) (2012) (2013) (2014) 
| Treatment regimen and treatment response definition
The treatment regimen consisted of subcutaneous, once-weekly injec- 
| Laboratory and liver fibrosis assessments
HCV RNA levels were quantitated using COBAS ® TaqMan ® HCV Test v2.0 (Roche Diagnostics) according to the manufacturer's instructions. The detailed protocol of the polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) method for genotyping the rs12979860 and rs8099917 SNPs has been described previously. 18 The study patients did not undergo liver biopsy because determining the histological severity is not required before starting 
| Statistical analysis
Categorical variables were expressed as frequencies and percent- SNPs, and the Linkage Disequilibrium (LD) between these SNPs was calculated. All baseline variables with P <.2 in the univariate analyses were entered to logistic regression models. Two regression models for multivariate analyses were used with the inclusion of one of the two analyzed SNPs in each model to avoid multicollinearity. 19 Odds ratios (OR) were calculated for the dichotomous variables and corresponding 95% confidence intervals were produced. P values <.05 were considered to be statistically significant. Statistical analyses were performed using SPSS version 20.0 (IBM SPSS, Chicago, IL, USA). Statistical graphs were generated using GraphPad Prism version 6.0 (GraphPad, San Diego, CA, USA).
| RESULTS
| Patients' baseline characteristics
Patients' demographics, clinical and laboratory characteristics are presented in Table 1 . The majority of the study population was comprised of male hemophilic patients. Their mean±SD age was 28.79±10.17 years.
HCV genotype-1a was the most prevalent, followed by HCV genotype3a. The cirrhosis criteria were observed in 31 (10.5%) patients. The CT variant of the rs12979860 SNP and the TT variant of the rs8099917 SNP were the most prevalent in the study group (45.9% and 57.6%, respectively; Table 1 ). The distributions of both rs12979860 and rs8099917 genotypes were in HWE (P=.86 and P=.99, respectively) and the two SNPs were in moderate LD (D'=1.0, r 2 =.55). The data were missed in <10% of patients. 
| Hepatitis C treatment response
| Factors associated with treatment response among patients with HCV genotype-1 infection
Among the baseline parameters measured in the HCV genotype-1 patients, age <24 years, BMI <25, absence of cirrhosis, HCV RNA level<400 000 IU/mL, rs12979860 CC and rs8099917 TT genotypes were significantly correlated with SVR, as determined by univariate analyses (Table 2) . Moreover, achieving RVR and cEVR during the treatment course was also associated with SVR among HCV genotype-1-infected patients (Table 2 ). In the multivariate analyses, all of the aforementioned baseline parameters remained statistically significant in their combined ability to predict SVR (P≤.05; Table 3 ). In logistic regression model 1 (with inclusion of rs12979860), the rs12979860 CC genotype was the strongest predictor of SVR, while in logistic regression model 2 (with inclusion of rs8099917), an absence of cirrhosis was the strongest predictor of SVR (Table 3) .
| Factors associated with treatment response in HCV genotype-3 infection
Among the baseline parameters in HCV genotype-3 infection, only the rs12979860 SNP was significantly associated with SVR (P=.048; Table 4 ).
In addition, cEVR was associated with attainment of SVR (P=.014).
Moreover, RVR did not predict SVR in patients with HCV genotype-3 infection. The data for RVR were not collected in 37% of patients owing to the routine management of the study population (Table 4 ).
| Sustained virologic response, virologic nonresponse, relapse, and rs12979860 in patients with HCV infection
HCV genotype-1-infected patients with the rs12979860 CC genotype exhibited the highest SVR rate, whereas patients with the CT and 
| DISCUSSION
This study demonstrated that among HCV-infected patients with inherited bleeding disorders, SVR was achieved in 62% of HCV genotype-1 patients and 88% of HCV genotype-3 patients-findings that are higher than those determined in similar studies. 20, 21 In patients with HCV genotype-1 infection, several variables were identified as key predictors of HCV treatment response: young age (<24), BMI <25, absence of cirrhosis, optimal low HCV RNA level (<400 000 IU/ mL), and rs12979860 CC and rs8099917 TT SNPs. Mancuso et al 22 found 42% and 85% SVR, respectively, among HCV genotype-1-and genotype-3-infected hemophilic patients. A study by Maor et al 23 showed a response rate of 37% SVR in 51 HCV-infected hemophilic cases. Another study conducted on 367 Iranian hemophilic patients who underwent treatment with PegIFN and RBV showed 61% SVR.
In the latter study, Age <24, HCV genotype-non-1, BMI <25 and baseline HCV RNA<600 000 IU/mL were independent predictors of SVR. 24 27 This study determined that SVR was strongly associated with RVR (OR=21) and cEVR (OR=11) in patients with HCV genotype-1 infection, which confirms the same observation determined previously among non-hemophilic HCV-infected individuals and indicates the importance of a rapid drop in HCV RNA level on HCV eradication. 28 Andriulli et al 29 found that achieving RVR was the main on-treatment predictor for achieving SVR. The current study demonstrated that attaining RVR played more of a key role in attaining SVR than either of the polymorphisms of the IFNL4 gene. The theory of viral kinetics maintains that RVR is a stronger predictor of SVR than baseline predictors. 7 Previously, it was assumed that polymorphisms of IFNL4 were alternative SVR predictors to RVR. However, these data are indicating instead that RVR is a reflection of known and unknown predictors of treatment outcome and cannot be replaced by polymorphisms of IFNL4. 7 The current study found a higher SVR rate in patients with HCV genotype-1 infection carrying rs12979860 CC and rs8099917 TT host genotypes than those cases with rs12979860
non-CC and rs8099917 non-TT genotypes. A recent study from Iran found that the rs12979860 CC genotype was significantly associated with achieving SVR. 13 Thompson et al 30 found that polymorphism(s) of IFNL4 was the best predictor of anti-HCV treatment response, above all other known baseline predictors. This study revealed that the HCV genotype-1 patients with rs12979860 CC or rs8099917 TT achieved 78% and 53% SVR, respectively. A recent study by Maor et al 23 showed
that SVR was attained in 70% and 50% of hemophilic patients who carried rs12979860 CC and rs8099917 TT genotypes, respectively.
Two meta-analyses reported that favorable rs12979860 genotypes are associated with SVR in HCV genotype-1 and -4 patients, but not in HCV genotype-3 patients. 31, 32 However, the results of this and other studies associating polymorphisms of IFNL4 and HCV The data were missed in less than 10% of patients. c The data were missed in more than 10% of patients.
T A B L E 2 The impact of baseline parameters and on-treatment response on achievement of SVR in patients with HCV genotype-1 infection The data were missed in less than 10% of patients. c The data were missed in more than 10% of patients.
T A B L E 4
The impact of baseline parameters and on-treatment response on achievement of SVR in patients with HCV genotype-3 infection T A B L E 3 Multivariate analysis of baseline predictors of SVR in patients with HCV genotype-1 infection 41 In the latter study, all cases achieved SVR 12 weeks after completing antiviral therapy. 41 Despite their ability to resolve HCV with a high SVR rate, these new DAAs are costly and thus may not be affordable in low-income communities. The limitation of the present study was its necessarily retrospective design; in our opinion, a prospective study design would produce more reliable results.
Moreover, the assessment of liver cirrhosis herein was performed via ultrasonography and physical exam findings in a proportion of patients.
In conclusion, given that hemophilic patients comprise a special patient group and the majority of these patients is infected with difficult-to-treat HCV genotypes, we believe that a decision-making policy for treating them is required. The present study showed a negative impact of different factors including the presence of cirrhosis, older age and high BMI on achieving SVR, thus, we recommend treating these patients as soon as possible. As approximately 80% of patients with HCV genotype-1 and the rs12979860 CC genotype did achieve SVR, and that the statistical correlation of these two factors with a favorable outcome is strong, we recommend conducting an evaluation of polymorphisms of IFNL4 before making a treatment decision. If the treatment-naïve patients harbor a favorable CC genotype, treatment with PegIFN and RBV can still be considered. Given that a high proportion (95%) of patients with HCV genotype-3 infection and rs12979860 CC and CT genotypes achieved SVR, a treatment course with PegIFN and RBV for this patient group is highly recommended.
Conversely, the patients with HCV genotype-3 infection and the rs12979860 TT genotype had a low (25%) SVR rate, which warrants consideration of IFN-free regimens for these patients. 
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